As the Society for Immunotherapy of Cancer (SITC) annual meeting kicks off in Houston, we are honored that SUPLEXA, Alloplex Biotherapeutics’ groundbreaking immunotherapy platform, has been recognized among the Top 100 presentations. This recognition speaks to SUPLEXA’s potential as a new approach in the fight against solid tumors by leveraging the power of patients’ own immune cells, trained ex vivo, without genetic modification.

Key Highlights to Be Presented:

• Top 100 Abstract #378: Showcases SUPLEXA’s unique pharmacodynamic profile, providing key insights into its immunomodulatory effects.
• Phase 1 Trial Results, Abstract #608: Final safety and efficacy outcomes from our first-in-human study, demonstrating SUPLEXA’s remarkable safety and promising clinical responses across multiple challenging cancer types.

With SUPLEXA, we’re retraining patients’ immune cells outside the body, restoring their natural ability to recognize and attack cancer effectively. Early data is inspiring—showing potential to benefit patients across tumor types including colorectal, renal, melanoma, breast cancer and beyond.

We invite all SITC 2024 attendees to meet John Pulford and Dr. Frank Borriello at the poster presentations on Saturday, November 9th for an in-depth look at SUPLEXA’s approach and its future potential in cancer care. Let’s connect and discuss what’s possible in cancer immunotherapy.

Thank you to all the collaborators, researchers and private investors who have helped make this vision a reality. We’re excited to move closer to transforming patient outcomes with SUPLEXA.